Contact
La Opinión de Zamora gives extensive coverage to the new incorporation of Angel Nebreda to the IRB Barcelona Oncology Programme. The “Signalling and Cell Cycle” group that he directs will focus its research on the p38 MAPK protein, which inhibits tumour initiation, and the RINGO/Speedy group of proteins which regulate the cell cycle. “We are very interested in studying aspects of the breast and colon cancers, and also in studying metastasis, wich links with the interests of the Institute and its group of experts, such as Eduard Batlle, Roger Gomis, Travis Stracker and Joan Massagué himself”, Nebreda said.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
